Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential.
Over a few short years, microarray gene expression profiling has permeated most areas of biomedical research. Microarrays are now poised to enter the more demanding realm of clinical applications. The prospect of using microarray data to derive biomarkers of disease or toxicity, predict prognosis, or select treatments raises the validity and reliability bar substantially higher. The potential future payoffs are huge in terms of faster approval of more efficacious and safer medical interventions, and a more personalized implementation of them. Arriving at the future sooner rather than later is the motivation for the FDA-led MicroArray Quality Control (MAQC) project. The widespread collaboration aims to assess achievable technical performance of microarrays and capabilities and limitations of methods for microarray data analysis.
D001709:Biotechnology; D003627:Data Interpretation, Statistical; D020869:Gene Expression Profiling / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data; D015233:Models, Statistical; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods / Q000592:standards* / Q000706:statistics & numerical data; D011786:Quality Control; D012313:RNA / Q000235:genetics / Q000592:standards; D012015:Reference Standards; D015203:Reproducibility of Results; D014481:United States; D014486:United States Food and Drug Administration
D012313:RNA